VideoPsychedelicsCannabisTrade To Black

What Investors Should See About Numinus Q3 Earnings

By Shadd Dales On Jul 19, 2023

Psychedelics are the topic of today’s Trade to Black podcast. Host Shadd Dales, millennial entrepreneur Anthony Varrell, and lead financial writer Benjamin A. Smith put their heads together to discuss the Q3 and 9 months earnings report of Numinus Wellness (TSE: NUMI) ended May 31.

On the topline, the company reported a double-digit 12.6% increase from the previous quarter, bringing their total revenues to $6.0m, supported by a 2.7% increase in average number of appointments per operating day and and strong performance by Cedar Clinical Research. This is compared to approximately ¾ of a million a year ago. Net loss was $7.29m versus $7.01m CAD a year ago. For the nine months, sales were $17.05m. They were $2.32m CAD a year ago. They also have a $2 million cash burn every month.

What does this Q3 report say about the company’s position in the industry, and does it mean that Numinus Wellness is wasting money? They’ve been prioritizing scaling clinics over treatment. Has this affected their financial report, and what does it mean for investors? We’ve got plenty of thoughts to share.

We’ll also delve into cannabis news and examine some of the most recent happenings. Curaleaf plans to also list on TSX, following in TerrAscend’s footsteps, and likewise is also making plans to eventually list on NASDAQ. How good are TerrAscend’s chances in managing to get on the NASDAQ? Find out what we think.

With these TSX listings, will cannabis companies still need SAFE Banking to pass? The debate over Section 10 is slowing down movement in Congress. If you missed our podcast about what’s causing the latest roadblock on SAFE Banking’s approval, you may want to catch it here.

Lastly, we’ll talk a few stocks. Canopy Growth’s latest status is now as a penny stock – at 37 cents, no less. Could Canopy Growth still go bullish, or could this the right time to jump to AYR instead? AYR looks like it might be undervalued, and we’ll explain why.

How are the other cannabis stocks performing in comparison? We’ll share the latest.

__________

* In accordance with an executed agreement between The Dales Report and Numinus Wellness, The Dales Report is engaged with the aforementioned on a 12-month contract for $10,000 per month, with the purpose of publicly disseminating information pertaining to Numinus Wellness via The Dales Report’s media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for The Dales Report services involves the receipt of a predefined monetary consideration, which may, on certain occasions, encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations. Please refer to the “Disclosures” section below, which is to be interpreted in conjunction with this disclaimer.

Shadd Dales is the Founder and President of The Dales Report and has an extensive background in the business media industry.

His work translates into over 15 years in mainstream media that included roles with BNN Bloomberg, CTV Properties and the iHeart Radio Network.

Shadd is considered one of the leading on air talents in both the cannabis and psychedelic space and has interviewed some of the most notable CEO names in the industry.

Shadd’s vision is to establish a content platform that is equivalent to a mainstream broadcast produced in a format that is relevant for today’s investor.